Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus CLARAVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUTANE versus CLARAVIS.
ACCUTANE vs CLARAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Category C
Category C
Retinoid
Retinoid